Asunto(s)
Arachis/inmunología , Técnicas y Procedimientos Diagnósticos/normas , Glycine max/inmunología , Isotretinoína/uso terapéutico , Hipersensibilidad al Cacahuete/tratamiento farmacológico , Anafilaxia/inmunología , Anafilaxia/prevención & control , Antígenos de Plantas/inmunología , Arachis/efectos adversos , Bases de Datos Factuales , Fármacos Dermatológicos/administración & dosificación , Fármacos Dermatológicos/uso terapéutico , Humanos , Inmunoglobulina E/inmunología , Isotretinoína/administración & dosificación , Monitoreo Fisiológico/métodos , Hipersensibilidad a la Nuez/tratamiento farmacológico , Hipersensibilidad a la Nuez/inmunología , Hipersensibilidad a la Nuez/prevención & control , Hipersensibilidad al Cacahuete/inmunología , Aceite de Soja/metabolismo , Glycine max/efectos adversosRESUMEN
Hypercalcaemia may complicate granulomatous diseases, such as tuberculosis and sarcoidosis, and various AIDS-related opportunistic infections and malignancies. We report here two patients with AIDS and disseminated Mycobacterium avium infection who developed symptomatic hypercalcaemia several weeks after commencing antimycobacterial chemotherapy, and in whom inappropriately elevated 1,25(OH)(2)D(3)levels were documented. Although vitamin D supplementation may have contributed, no other cause for the hypercalcaemia was found. The biochemical and clinical similarities between these cases and other hypercalcaemic granulomatous diseases suggest a common mechanism related to macrophage activation and dysregulated vitamin D production.
Asunto(s)
Infecciones Oportunistas Relacionadas con el SIDA/complicaciones , Síndrome de Inmunodeficiencia Adquirida/complicaciones , Antibacterianos/uso terapéutico , Hipercalcemia/complicaciones , Mycobacterium avium , Tuberculosis Miliar/complicaciones , Síndrome de Inmunodeficiencia Adquirida/sangre , Adulto , Aminoglicósidos , Antibacterianos/efectos adversos , Antituberculosos/uso terapéutico , Calcio/sangre , Quimioterapia Combinada , Fluoroquinolonas , Humanos , Hipercalcemia/inducido químicamente , Masculino , Esteroide Hidroxilasas/sangre , Tuberculosis Miliar/tratamiento farmacológicoAsunto(s)
Amdinocilina Pivoxil/uso terapéutico , Amdinocilina/uso terapéutico , Antibacterianos/uso terapéutico , Pruebas de Sensibilidad Microbiana , Infecciones Urinarias/microbiología , Administración Oral , Amoxicilina/uso terapéutico , Ampicilina/uso terapéutico , Combinación de Medicamentos/uso terapéutico , Humanos , Ácido Nalidíxico/uso terapéutico , Nitrofurantoína/uso terapéutico , Estudios Prospectivos , Sulfametoxazol/uso terapéutico , Trimetoprim/uso terapéutico , Combinación Trimetoprim y Sulfametoxazol , Infecciones Urinarias/tratamiento farmacológicoRESUMEN
The in-vitro sensitivity to ampicillin, cotrimoxazole, nitrofuratoin, nalidixic acid and mecillinam was determined for 511 organisms isolated from 399 consecutive urine specimens. Urine specimens were divided into those of hospital in-patient origin (group B). Group B organisms were more sensitive than group A organisms. Over 75 percent of all group B organisms were sensitive to nitrofurantoin, nalidixic acid and mecillinam. Organisms resistant to multiple antibiotics were more frequently isolated from group A catheterized patients and are now less frequently isolated than in 1983. The antibiotic implications of these findings are discussed (AU)
Asunto(s)
Humanos , Amdinocilina Pivoxil/uso terapéutico , Antibacterianos/uso terapéutico , Pruebas de Sensibilidad Microbiana , Infecciones Urinarias/microbiología , Amdinocilina/uso terapéutico , Administración Oral , Amoxicilina/uso terapéutico , Ampicilina/uso terapéutico , Combinación de Medicamentos/uso terapéutico , Ácido Nalidíxico/uso terapéutico , Nitrofurantoína/uso terapéutico , Sulfametoxazol/uso terapéutico , Trimetoprim/uso terapéutico , Infecciones Urinarias/tratamiento farmacológico , Estudios ProspectivosRESUMEN
The in-vitro sensitivity to ampicillin, cotrimoxazole, nitrofuratoin, nalidixic acid and mecillinam was determined for 511 organisms isolated from 399 consecutive urine specimens. Urine specimens were divided into those of hospital in-patient origin (group A) and those from comunity patients(group B). Group B organisms were more sensitive than group A organisms. Over 75% of all group B organisms were sensitive to nitrofurantoin, nalidixic acid and mecillinam. Organisms resistant to multiple antibiotics were more frequently isolated from group A catheterized patients and are now less frequently isolated than in 1983. The antibiotic implications of these findings are discussed